

January 05, 2021

**TAKE/BSE/2020-21**

The Manager  
 Dept. of Corporate Services-Listing  
 Bombay Stock Exchange Limited,  
 P. J. Towers, Dalal Street,  
 Mumbai - 400001  
 Scrip Code: 532890

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations") - Revision of Credit Rating.**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that CARE Ratings Limited (the "Credit Rating Agency") has revised the Credit Rating of the Company.

In accordance with the Regulation, please find below the details of the revision in rating of the Company.

Facilities	Existing Rating	Revised Rating
Issuer Rating	CARE BB+ (Is); Negative [Double B Plus (Issuer Rating); Outlook: Negative]	Revised from CARE BBB (Is); Negative [(Triple B) (Issuer Rating; Outlook: Negative)]

Kindly take the above information on your records.

Thanking you.  
 Yours faithfully,


**For TAKE Solutions Limited**



**Shobana N.S**  
**Executive Director**  
**DIN: 01649318**



Encl: As above



## TAKE Solutions Limited

January 04, 2021

### Ratings

Facilities	Amount (Rs. crore)	Rating <sup>1</sup>	Rating Action
Issuer Rating#	-	CARE BB+ (Is); Negative (Double B Plus (Issuer Rating); Outlook: Negative)	Revised from CARE BBB (Is); Negative(Triple B (Issuer Rating); Outlook: Negative)

*Details of facilities in Annexure 1*

#The issuer rating is subject to the company maintaining overall gearing not exceeding 1.25x

### Detailed Rationale & Key Rating Drivers

The revision in the rating assigned to TAKE Solutions Limited (TAKE) takes into account the tightening liquidity position in the group marked by over dues extending beyond 30 days in the packing credit facility in one of its subsidiaries, Navitas LLP. While CARE notes that the over dues have since been regularized, the operating environment for the Take group continues to remain challenging further accentuated by the fresh wave of lockdown restrictions being imposed globally. Challenging operating environment is expected to result in lower site utilizations and put pressure on the liquidity position of the company in the near term. The company has been exploring various options including capital raising at subsidiary level, however, nothing material has fructified till date and with higher repayments coming up in the near term the liquidity position is expected to remain stressed.

The rating continues to be constrained by revenue concentration with high and increasing dependence on the US market after liquidation proceedings in the German subsidiary, fortunes linked with changing dynamics of the global pharma industry, relatively small size of operations in a highly competitive industry and risks associated with consolidation of the acquired businesses.

The rating, however, continues to factor in the long track record of operations and domain expertise in Life Science (LS) segment. In view of the company operating and generating majority of its revenue through various subsidiaries, the rating is based on TAKE's group operations as a whole and on the financial position of the company on a consolidated basis.

### Outlook: Negative

The outlook continues to remain 'Negative' on account of the continued losses incurred by TAKE on account of the business disruptions arising out of the COVID pandemic. However, the outlook may be revised to stable if there is an improvement in the business environment with the company being able to profitably scale up operations and improve its liquidity position.

### Rating Sensitivities

#### Positive Factors

- Improvement in liquidity position
- Ability to successfully integrate the recent large-sized acquisitions and generate adequate returns from the same.
- Ability to commence operations across all its facilities and stabilise revenue generation and maintain healthy profitability.

#### Negative Factors

- Increase in debt levels resulting in leverage levels, viz., overall gearing above 1.25x.
- Deterioration in collections period beyond 120 days.
- Extended impact of COVID-19 pandemic on the operations of the company resulting in a large fall in the revenues and profits.

### Detailed description of the key rating drivers

#### Key Rating Weaknesses

##### *Disruption in operations and drop in Income levels*

TAKE has been reporting consistent growth in the revenues also aided by acquisitions from time to time. During FY20 (refers to the period April 1 to March 31), TAKE (Consolidated) has achieved a growth of 8.53% in TOI on y-o-y basis and a CAGR of 21% for the last five years. The increase in revenue was mainly contributed by growth in LS segment by 10.57% to Rs.2,079 crore in FY20. However, from Q4FY20 onwards, the company has reported a sharp drop in the operating income on account of the Covid-19 pandemic, which has restricted access to hospitals for trial, etc. As compared to 15-20% utilization at trial sites during Q1FY21, site utilization levels were around 45% in September 2020. The revenue for the period Q2FY21 was Rs.170.73 crores as against revenue of Rs.165.89 crore in Q1FY21. The company reported a TOI of Rs.336.63 crore for H1FY21 as compared with Rs.1191.13 crore for H1FY20.

<sup>1</sup>Complete definitions of the ratings assigned are available at [www.careratings.com](http://www.careratings.com) and in other CARE publications.

***Losses being reported and consequent impact on liquidity***

The PBILDT margin of the company has moderated to around 7.6% for FY20 as compared with 19.19% in FY19. This was largely on account of sharp drop in the operating income during Q4FY20. This sharp drop has led to the company reporting a loss PBDIT level in Q4FY20 and tempered the overall profitability for the year.

Limited revenue visibility on account of passive operating level and non-availability of minimum-pay clause in the agreements with clients, compound with the high fixed-cost intensive nature of clinical trial business is expected to put pressure on profitability. Rationalization of costs by way of head count reduction mainly in the western geographies wherein labor costs are high, off-shoring of work to Indian offices, wage cuts and cost cuts with respect to S&G Expenses have been implemented in H1FY21. However, timely commencement and scaling of operations apart from cost rationalization would be key to profitable operations of the company. The company has reported loss before tax of Rs.354.36 crore for H1FY21 as against profit before tax of Rs. 117.11 crore in H1FY20. The loss before tax is Rs.114.60 crore for Q2FY21 as against loss before tax of Rs. 240.93 crore reported for Q1FY21. The heavy losses have impacted the liquidity position of the company with cash generation from operations being severely impacted.

***Highly dependent on US market***

The revenue from USA region contributed 85% of the total revenue in FY20 (PY: 84%) on the back of higher orders from the region. TAKE's acquisitions in USA – KAI Research Inc. (clinical research organisation) and Dataceutics Holdings Inc. (clinical functional service provider) in FY19 and liquidation of the German subsidiary will further increase the concentration of the revenues in this market. The contribution in Asia-Pac stood at 13% (PY: 12%) and share of Europe declined to 2% (PY: 4%) of the total revenues in FY20.

***Changing dynamics of global pharma industry***

Pharmaceutical industry is tightly regulated all over the world with stringent norms and regulations. Structural reforms by governments stringent regulation both in regulated and semi-regulated market, intensification of competition has led to pricing pressure impacting the profitability of the industry players.

Competition and increased pricing pressure on pharma companies has resulted in cost cutting measures adopted by them to remain competitive, resulting in reduced business for the companies operating in the pharma/drug market value chain including IT service providers. This has resulted in vendor consolidation approach adopted by pharma companies forcing tier-I/tier-II companies/service providers in the industry to move up the value chain. Pure play clinical research organizations (CRO) have also started providing IT services.

***Relatively small player operating in competitive environment and risks associated with consolidation of acquired business***

TAKE has relatively moderate scale of operations in the global market. Presence of number of mid-sized technology companies that offer technology solutions to various pharmaceutical companies for regulatory submission and pharmacovigilance poses a stiff competition for the company. TAKE follows the approach of acquiring companies and increases its presence in the value chain. The ability of the company to successfully integrate the operations, manage overlapping customer profiles and monetize the integrated domain and technical expertise for long-term benefits is critical for its prospects.

**Key Rating Strengths*****Long track record of operations***

TAKE was incorporated as a private limited company in December 2000. The company initially started with the Supply chain management solutions and over the years, the company has emerged as a significant player in the niche life sciences segments through various acquisitions and investments across the globe. The inorganic route has helped it acquire and enhance the domain expertise, enter new geographies, acquire new clients and augment its product and service offerings. With long track record, TAKE has established relationships with reputed clients in LS segment which includes leading global pharma companies. The operations are overseen by an eight-member board including five independent directors. Mr Srinivasan H.R. is the Vice Chairman and Managing Director of the company. The company has seen resignation of one of the co-founders, the CEO, CFO and further the company secretary in recent times. Mr. Lalit Mahapatra (erstwhile CFO of Ecron Acunova Limited), who has been associated with the group, has taken over as the CFO of TAKE Solutions with effect from July 01, 2020 and Mr. P. Srinivasan has been appointed as the company secretary with effect from January 18, 2021

***Focus on LS business segment backed by strong domain expertise***

TAKE had initially started in Supply Chain Management space and later expanded to Life Science segment providing opportunities for the company to grow and establish itself. However, in recent years, TAKE has been focusing more on LS segment. LS segment contributed 94% of the revenue in FY20 as against 92% in FY19. The revenue from LS segment witnessed growth of 10.57%, however, the SCM segment witnessed de-growth of 15.66% in FY20.

In September 2020, the board of TAKE has also approved sale of entire stake (58%) held in subsidiary APA Engineering Pvt Ltd. which is the supply chain division of the company. With this divestment, the company will exit the supply chain division.

## Prospects

Given the socio-economic conditions arising out of the COVID-19 pandemic globally, the business environment for TAKE has been significantly affected and the company is likely to witness a drop in sales in the current year. Furthermore, considering the high fixed cost nature of the business, largely employee cost and interest costs arising out of higher working capital requirement in recent times the profitability of the company is likely to be under pressure in the near term. Going forward, the revised operating procedures specified for conducting clinical trials across geographies is expected to prolong timelines for conducting trials and trim down margins in general, which would impact both revenue generation as well as profitability.

## Liquidity – Stretched

The liquidity position has weakened with subdued cash generation from operations. CARE as part of its due diligence exercise has become aware of over-dues beyond 30 days in recent months in the packing credit facilities of Navitas LLP, which have since been regularized. CARE notes that while the said facility has been guaranteed by Take Solutions Ltd, the guarantee was not invoked. The company has almost utilized the entire CC limit in Ecron Acunova Limited and Navitas LLP.

In the light of the lockdown imposed, where cash generation is stressed, the company has obtained moratorium on its working capital facilities and term loan in Ecron Acunova Limited. Ecron Acunova Limited has been sanctioned working capital term loan of Rs.6.99 crore under the Guaranteed Emergency Credit Line Scheme for a period of 4 years including a moratorium of 1 year. The company has also obtained a sanction of a term loan of Rs.40 crore in Ecron Acunova Limited and is actively working on recovery of debtors and unwinding some of the advances given to the supplier and technology partners to meet immediate liquidity requirement.

## Analytical approach:

Considering the significant financial as well as operational linkages of TAKE with its subsidiaries, the consolidated financials of TAKE (together with its subsidiaries) have been considered for analysis. TAKE on standalone basis does not have any major operations. As on September, 2020, TAKE has four subsidiaries and nineteen step-down subsidiaries. The board of TAKE has also approved sale of entire stake (58%) held in subsidiary APA Engineering Pvt Ltd. which is the supply chain division of the company and the same is reflected as "Asset held for sale" as on September 30, 2020. The holding company of TAKE is TAKE Solutions Pte. Ltd, Singapore, which is held by the promoters and is an investment company with no major operations. The companies considered for consolidation has been given as Appendix

## Applicable Criteria

[Criteria on assigning 'outlook' and 'credit watch' to Credit Ratings](#)

[CARE's Policy on Default Recognition](#)

[Rating Methodology: Consolidation and Factoring Linkages in Ratings](#)

[Rating Methodology - Service Sector Companies](#)

[Financial ratios – Non-Financial Sector](#)

[CARE's Issuer Rating](#)

[Criteria for Short Term Instruments](#)

## About the Company

TAKE Solutions Limited (TAKE) is a product-led (mainly in pharma/ biotech) IT solutions and Services Company with focus in, Life Sciences (LS) segment. TAKE's global headquarters is in Chennai, India. Two professionals, Mr H R Srinivasan (Ex-MD of Sembcorp Logistics, Singapore) and Mr D V Ravi founded TAKE as a private limited company in 2000. Mr D V Ravi indirectly held 13.55% of shares in TAKE Solutions Limited. In June 2020, he sold 8.24% of shares via block deal in Stock Exchange. Mr D V Ravi, who resigned as director, continues to hold 5.24% in TAKE Solutions Limited.

Brief Financials (Rs. crore) (TAKE Solutions Ltd. – Consolidated)	FY19 (A)	FY20 (A)
Total income	2,048.33	2,238.67
PBILDT	392.98	194.69
PAT	178.37	-10.95
Overall gearing (times)	0.39	0.46
Interest coverage (times)	15.71	4.72

A: Audited

## Note:

1. Operating Lease Payable is considered for Overall Gearing calculation.
2. Current maturities of long term debt are not included in the capital employed and other debt-related ratios.

**Status of non-cooperation with previous CRA – Not Applicable**

**Any other information – Not Applicable**

**Rating History for last three years:** Please refer Annexure-2

**Covenants of rated instrument/ facility:** Not Applicable

**Complexity level of various instruments rated for this company:** Annexure 4

**Annexure-1: Details of Instruments/Facilities**

Name of the Instrument	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. crore)	Rating assigned along with Rating Outlook
Issuer Rating-Issuer Ratings	-	-	-	0.00	CARE BB+ (Is); Negative

**Annexure-2: Rating History of last three years**

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating history			
		Type	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2020-2021	Date(s) & Rating(s) assigned in 2019-2020	Date(s) & Rating(s) assigned in 2018-2019	Date(s) & Rating(s) assigned in 2017-2018
1.	Fund-based - LT-Cash Credit	LT	-	-	-	-	-	1)Withdrawn (11-Apr-17)
2.	Commercial Paper	ST	-	-	-	-	1)Withdrawn (14-Nov-18)	1)CARE A1+ (08-Dec-17) 2)CARE A1+ (21-Sep-17)
3.	Issuer Rating-Issuer Ratings	Issuer rat	0.00	CARE BB+ (Is); Negative	1)CARE BBB (Is); Negative (24-Nov-20) 2)CARE A-(Is); Negative (10-Aug-20) 3)CARE A+ (Is); Negative (22-Jun-20) 4)CARE AA- (Is); Negative (19-May-20)	1)CARE AA- (Is); Stable (04-Mar-20)	1)CARE AA- (Is); Stable (21-Nov-18)	1)CARE AA- (Is); Stable (08-Dec-17) 2)CARE AA- (Is); Stable (21-Sep-17)

**Annexure-3: Detailed explanation of covenants of the rated instrument / facilities- NA**

**Annexure 4: Complexity level of various instruments rated for this Company**

Sr. No.	Name of the Instrument	Complexity Level
1.	Issuer Rating-Issuer Ratings	Simple

**Appendix:**
**Details of Subsidiaries:**

<b>Name of the Company</b>
Navitas LLP
TAKE Solutions Global Holdings Pte. Ltd.
Ecron Acunova Limited
APA Engineering Pvt. Ltd. (Consolidated as Asset Held for Sale)
TAKE Solutions ESOP Trust

**Details of Step-down Subsidiaries:**

<b>Name of the Company</b>
APA Engineering Pte Ltd, Singapore (Consolidated as Asset Held for Sale)
APA Engineering Inc., USA (Consolidated as Asset Held for Sale)
TAKE Solutions Information Systems Pte. Ltd., Singapore
TAKE Enterprise Services Inc., USA
TAKE Innovations Inc., USA
Navitas Life Sciences Holdings Ltd., UK
Navitas Life Sciences Limited
Acunova Life Sciences Inc., USA
Navitas Life Sciences Company Ltd. (fka Ecron Acunova Company Ltd.), Thailand
Navitas Life Sciences GmbH (fka Ecron Acunova GmbH), Germany
Acunova Life Sciences Ltd., UK
Ecron Acunova Sdn Bhd, Malaysia
Million Star Technologies Ltd., Mauritius
Intelent Inc., USA
Navitas Inc., USA
Navitas Lifesciences S.A.S, Colombia
Ecron Acunova Sp. Z. p. o., Poland
Ecron Acunova LLC, Russia
Navitas Life Sciences AS (fka Econ Acunova AS), Denmark
Ecron LLC, Ukraine
Navitas Life Sciences Pte. Ltd. (fks Ecron Acunova Pte. Ltd.), Singapore

**Note on complexity levels of the rated instrument:** CARE has classified instruments rated by it on the basis of complexity. This classification is available at [www.careratings.com](http://www.careratings.com). Investors/market intermediaries/regulators or others are welcome to write to [care@careratings.com](mailto:care@careratings.com) for any clarifications.

**Contact us****Media Contact**

Name: Mradul Mishra  
Contact no. – +91-22-6837 4424  
Email ID – [mradul.mishra@careratings.com](mailto:mradul.mishra@careratings.com)

**Analyst Contact**

Name: Mr. P Sandeep  
Contact no.: 044 2850 1000  
Email ID: [sandeep.prem@careratings.com](mailto:sandeep.prem@careratings.com)

**Relationship Contact**

Name: Mr. V. Pradeep Kumar  
Contact no. : 044 2850 1001  
Email ID: [pradeep.kumar@careratings.com](mailto:pradeep.kumar@careratings.com)

**About CARE Ratings:**

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

**Disclaimer**

CARE's ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE's ratings do not convey suitability or price for the investor. CARE's ratings do not constitute an audit on the rated entity. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE or its subsidiaries/associates may also have other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is, inter-alia, based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

**\*\*For detailed Rationale Report and subscription information, please contact us at [www.careratings.com](http://www.careratings.com)**